



thrive-131

Therapy for Reduction with Inclacumab of VOC Episodes

Treating patients who have

SICKLE CELL DISEASE?

**Consider clinical research.
Make a referral. Make a difference.**

The Thrive-131 clinical research study will evaluate the safety and efficacy of an investigational monoclonal antibody to reduce the incidence of vaso-occlusive crises in participants with sickle cell disease.

Your patients may qualify to participate if they meet the following criteria:

- Confirmed diagnosis of sickle cell disease.
- Male or female, ≥ 16 years of age.
- Have experienced 2-10 vaso-occlusive crises in the last 12 months.

Additional criteria apply.

Your referrals make sickle cell disease research possible. Your patients' participation will be strictly study-related, and they will remain under your care.

For more information or to refer a patient, please contact: